Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
BUSINESS
MSD Japan to Get Women’s Health Spinoff Organon Up and Running in October: Chief
Jannie Oosthuizen, Japan chief of Merck & Co., said on April 6 that a new legal entity that will take over its women’s health and legacy brands has now been registered in the country, with the drug giant planning to…
To read the full story
Related Article
- Organon Japan to Focus on Women’s Health, Enrich Offerings with Global Products: President
June 29, 2021
- MSD Japan Spins Off Organon Women’s Health Biz, Ryota Sakurai Takes Helm
June 4, 2021
- MSD Japan Suffers 7% Sales Dip on Repeated Keytruda Re-Pricing, Urges Policy Rethink
April 21, 2021
- MSD Japan Embarking on 2-Step Spinoff for Women’s Health, Legacy Brands
February 28, 2020
BUSINESS
- Oncolys Files Telomelysin in Japan, Eyes API Manufacturing Expansion in Asia
December 16, 2025
- Eisai Flags Nitrosamine Found in Merislon, Says Supply to Continue
December 16, 2025
- Mochida to Bring in Morning Sickness Drug from Canada’s Duchesnay
December 16, 2025
- Global PIII Trial Halted for Arcus-Partnered TIGIT Drug: Taiho
December 16, 2025
- Vyvdura Now Available in Prefilled Syringe: Argenx Japan
December 16, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…